SWOG clinical trial number
C9687
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Cancer.
Closed
Phase
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Pts must have biopsy proven persistence or recurrence of prostate cancer with no evidence of metastatic disease at the time of biopsy. Pts must have a PS of 0-1. Pts must have been treated with >/= 60 cGy external beam RT or brachytherapy for clinical states T1-2, NX, M0 PC w/PSA < / = to 30 ng/ml prior to RT. It must be > / = 18 mos since last RT and > / = to 3 mos since last adj hormonal tx. Pts dx'ed w/another malignancy w/in previous 5 years (except for non-melanoma skin ca or Ta bladder ca) are not eligible. Pts must have a PSA of < / = 20 ng/ml obtained within 30 days prior to registration.
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase